Distribute EVEDA across Oceania and beyond
Country-level distribution partnerships with full regulatory support, training, and ongoing clinical quality assurance. TGA and Medsafe listed, with expansion pathways for new markets.
Healthcare screening where it is needed most
Pacific Island nations face the world's highest rates of diabetes and obesity, with populations dispersed across thousands of islands, chronic workforce shortages, and limited laboratory infrastructure. EVEDA was designed for exactly these conditions.
Pacific Islands
Fiji, Papua New Guinea, Samoa, Tonga, Vanuatu, Solomon Islands, and across Melanesia, Polynesia, and Micronesia. Purpose-built for remote island health settings.
Southeast Asia
Emerging market opportunities in rural and community health screening across the region. Distribution partnerships under development.
Middle East & Africa
Portable, self sufficient health screening for settings with infrastructure constraints. Expression of interest welcome from qualified distributors.
What EVEDA provides to international partners
We support country-level distributors with everything needed to deploy, operate, and scale EVEDA in your market. From regulatory navigation to operator training and ongoing clinical quality assurance.
Distributor support
- Regulatory pathway support for your market
- In-country operator training and certification
- Consumables supply chain management
- Localised Health Passport app deployment
- DAX analytics configured for local health priorities
- Marketing materials and co-brand support
- Ongoing clinical quality assurance (RCPA QAP participation)
- Dedicated international partnership team
Regulatory foundations for international deployment
TGA (Australia)
ARTG 346638 (Class IIb device system) and ARTG 342561 (Class I clinical software). Australian regulatory foundation for Oceania deployment.
Medsafe (New Zealand)
Registered with New Zealand's medicines and medical devices safety authority under the Trans-Tasman framework.
Expansion pathways
EVEDA is actively pursuing additional regulatory pathways. Contact our international team to discuss registration requirements for your market.
One integrated device, 300+ screening tests
The EVEDA HubX captures data across six core health systems using just five drops of blood and a urine sample. No venepuncture. No lab. Results in 15 minutes.
